Role of Dashamula saindhav sarpi-Oral and Nasya in Migraine

A comparative study to evaluate the efficacy of Nasya(Dashamula Saindhav Sarpi) and oral(Dashamula Saindhav Sarpi) in Ardhavabhedaka W.S.R.to Migraine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/12/022512

Enrollment

Registered

2019-12-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Intervention1: DASHMULA SAINDHAV SARPI ORALLY: GROUP A DOSE OF DASHMOOL SAINDHAV SARPI 1 PALA I.E.48 GRAMS IN TO TWO DIVIDED DOSE FOR 2 MONTHS Control Intervention1: DASHMULA SAINDHAV SARPI NASYA: GRO

Eligibility

Inclusion criteria

Inclusion criteria: Patients having sign and symptoms of Ardhavabhedaka (Migraine)according to Ayurvedic classics as well as Modern Parameters.

Exclusion criteria

Exclusion criteria: All patients contraindicated for Nasya,Sinusitis, hypertension, Severe depression or psychiatric disorders,Referred headache,Cluster headache,Trigeminal neuralgia,space occupying lesions.

Design outcomes

Primary

Measure	Time frame
Improvement in overall clinical signs and symptoms of Migraine based on the scale of International Headache SocietyTimepoint: 2 months	—

Secondary

Measure	Time frame
Analysis of effect of Dashmool saindhav sarpi in Migraine when administered nasally and orallyTimepoint: 2 months	—

Countries

India

Contacts

Public ContactDr GIRISH NARAIN RAI

VAIDYA YAGYA DUTT SHARMA AYURVEDIC COLLEGE KHURJA UP

girishnarinrai@gmail.com8218680766

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026